Chemotherapy of Pancreatic Cancer

  • Margaret Tempero

Abstract

In contrast to the improvements in overall survival for most other gastrointestinal tract cancers, the 5-yr survival of patients with pancreatic cancer sits at a dismal 4% (1), suggesting that there has been no significant improvement in early diagnosis or therapy. In 1998, an estimated 27,600 new cases will be diagnosed (1). This disease is the fourth leading cause of cancer death in men and the fifth cause of cancer death in women.

Keywords

Doxorubicin Octreotide Mitomycin Adriamycin Mitoxantrone 

Preview

Unable to display preview. Download preview PDF.

Unable to display preview. Download preview PDF.

References

  1. 1.
    Parker SL, Tong T, Bolden S, and Wingo PA. Cancer Statistics, 1997. CA Can J Physicians 1997; 47:5–27.CrossRefGoogle Scholar
  2. 2.
    Brand R and Matamoros A. Imaging techniques in the evaluation of adenocarcinoma of the pancreas. Dig Dis 1997; in press.Google Scholar
  3. 3.
    Muller ME, Meyenberger C, Bertschinger P, Schaer R, and Marincek B. Pancreatic tumors: evaluation of endoscopic US, CT, and M R imaging. Radiology 1994; 190:745–751.PubMedGoogle Scholar
  4. 4.
    Carr-Locke DL, Ball TJ, Connors PJ, Cotton PB, Geenen JE, Hawes RH, et al. Multicenter randomized trial of wallstent biliary endoprosthesis versus plastic stents. Gastrointest Endosc 1993; 3:310.Google Scholar
  5. 5.
    Lillemoe KD, Cameron JL, Kaufman HS, Yeo CJ, Pitt HA, and Sauter PK. Chemical splanchnicectomy in patients with unresectable pancreatic cancer. A prospective randomized trial. Ann Surg 1993; 217:447–455.Google Scholar
  6. 6.
    Passik SD and Breithart WS. Depression in patients with pancreatic carcinoma: Diagnostic and treatment issues. Cancer 1996; 78:615–626.PubMedGoogle Scholar
  7. 7.
    Crist DW and Cameron JL. The current status of the Whipple operation for periampullary carcinoma. Adv Surg 1994; 25:21–49.Google Scholar
  8. 7a.
    Green S and Weiss GR. Southwest Oncology Group standard response criteria, endpoint definitions and toxicity criteria. Invest New Drugs 1992; 10:239–253.PubMedCrossRefGoogle Scholar
  9. 8.
    Freeny PC. Radiologic diagnosis and staging of pancreatic ductal adenocarcinoma. Radiol Clin North Am 1989; 27: 121–128.PubMedGoogle Scholar
  10. 9.
    Casper ES, Green MR, Kelsen DP, Heelan RT, Brown TD, Flombaum CD, Trochanowski B, and Tarassoff PG. Phase II trial of gemcitabine (2,2′-difluorodeoxycytidine) in patients with adenocarcinoma of the pancreas. Invest New Drugs 1994; 12:29–34.PubMedCrossRefGoogle Scholar
  11. 10.
    Carmichael J, Fink U, Russell RCG, Spittle MF, Harris A, Spiessl G, et al. Phase II study of gemcitabine in patients with advanced pancreatic cancer. Br J Cancer 1995; 73:101–105.CrossRefGoogle Scholar
  12. 11.
    Burris HA, Moore MJ, Andersen J, Green MR, Rothenberg ML, Modiano MR, et al. Improvements in survival and clinical benefit with gemcitabine as first-line therapy for patients with advanced pancreatic cancer: a randomized trial. J Clin Oncol 1997; 15:2403–2413.PubMedGoogle Scholar
  13. 12.
    Rothenberg ML, Moore MJ, Cripps MC, Andersen JS, Portenoy RK, Burris HA, et al. A phase II trial of gemcitabine in patients with 5-FU refractory pancreas cancer. Ann Oncol 1996; 7:347–353.PubMedCrossRefGoogle Scholar
  14. 13.
    Schein PS, Lavin PT, Moertel CG, Frytak S, Hahn RG, O’Connell MJ, et al. Randomized phase II clinical trial of adriamycin, methotrexate, and actinomycin-D in advanced measurable pancreatic carcinoma: a Gastrointestinal Tumor Study Group report. Cancer 1978; 42:19–22.PubMedCrossRefGoogle Scholar
  15. 14.
    Inamasu M, Oishi N, Chen T, Legha S, McCracken J, Balcerzak S, et al. Phase II trial of amsacrine in pancreatic carcinoma: a Southwest Oncology Group study. Cancer Treatment Rep 1984; 68:1411–1412.Google Scholar
  16. 15.
    Kajanti MJ and Pyrhönen SO. Phase II trial of oral carmofur in advanced carcinoma. Ann Oncol 1991; 2:765–766.PubMedGoogle Scholar
  17. 16.
    Wils J, Bleiberg H, Blijham G, Dalesio O, Duez N, Lacave A, and Splinter T. Phase II study of epirubicin in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 1985; 21:191–194.PubMedCrossRefGoogle Scholar
  18. 17.
    Philip PA, Carmichael J, Tonkin K, Buamah PK, Britton J, Dowsett M, and Harris AL. Hormonal treatment of pancreatic carcinoma: a phase II study of LHRH agonist goserelin plus hydrocortisone. Br J Cancer 1993; 67:379–382.PubMedCrossRefGoogle Scholar
  19. 18.
    Loehrer PJ, Williams SD, Einhorn LH, and Ansari R. Ifosfamide: an active drug in the treatment of adenocarcinoma of the pancreas. J Clin Oncol 1985; 3:367–372.PubMedGoogle Scholar
  20. 19.
    Bukowski RM, Fleming TR, Macdonald JS, Oishi N, Taylor SA, and Baker LH. Evaluation of combination chemotherapy and phase II agents in pancreatic adenocarcinoma. A Southwest Oncology Group study. Cancer 1993; 71:322–325.Google Scholar
  21. 20.
    Friess H, Büchler M, Beglinger C, Weber A, Kunz J, Fritsch K, Dennler HJ, and Beger HG. Low-dose octreotide treatment is not effective in patients with advanced pancreatic cancer. Pancreas 1993; 8:540–545.PubMedCrossRefGoogle Scholar
  22. 21.
    Ahlgren JD. Pancreatic cancer: chemotherapy of advanced disease. In: Ahlgren JD and Macdonald JS (eds), Gastrointestinal Oncology, JB Lippincott, Philadelphia, 1992; pp. 227–235.Google Scholar
  23. 22.
    Keating JJ, Johnson PJ, Cochrane AMG, Gazzard BG, Krasner N, Smith PM, et al. A prospective randomised trial of tamoxifen and cyproterone acetate in pancreatic carcinoma. Br J Cancer 1989; 60:789–792.PubMedCrossRefGoogle Scholar
  24. 23.
    Omura GA, Bartolucci AA, Lessner HE, and Hill GJ. Phase II evaluation of amsacrine in colorectal, gastric, and pancreatic carcinomas: a Southeastern Cancer Study Group trial. Cancer Treatment Rep 1984; 68:929–930.Google Scholar
  25. 24.
    Hochster H, Green MD, Speyer JL, Wernz JC, Blum RH, and Muggia FM. Activity of epirubicin in pancreatic carcinoma. Cancer Treatment Rep 1986; 70:299–300.Google Scholar
  26. 25.
    Gastrointestinal Tumor Study Group. Phase II trials of single agents Baker’s antifol, diaziquone, and epirubicin in advanced pancreatic cancer. Cancer Treatment Rep 1987; 71:865–867.Google Scholar
  27. 26.
    Ajani JA, Abbruzzese JL, Goudeau P, Faintuch JS, Yeomans AC, Boman BM, Nicaise C, and Levin B. Ifosfamide and mesna: marginally active in patients with advanced carcinoma of the pancreas. J Clin Oncol 1988; 6:1703–1707.PubMedGoogle Scholar
  28. 27.
    Gastrointestinal Tumor Study Group. Ifosfamide is an inactive substance in the treatment of pancreatic carcinoma. Cancer 1989; 64:2010–2013.CrossRefGoogle Scholar
  29. 28.
    Allegretti A, Lionetto R, Saccomanno S, Paganuzzi M, Onetto M, Martinoli C, et al. LHRH analogue treatment in adenocarcinoma of the pancreas: a phase II study. Oncology 1993; 50:77–80.PubMedCrossRefGoogle Scholar
  30. 29.
    Wong A, Chan A, and Arthur K. Tamoxifen therapy in unresectable adenocarcinoma of the pancreas. Cancer Treatment Rep 1987; 71:749–750.Google Scholar
  31. 30.
    Cullinan SA, Moertel CG, Fleming TR, Rubin JR, Krook JE, Everson LK, et al. A comparison of three chemotherapeutic regimens in the treatment of advanced pancreatic and gastric carcinoma. JAMA 1985; 253:2061–2067.PubMedCrossRefGoogle Scholar
  32. 31.
    DeCaprio JA, Mayer RJ, Gonin R, and Arbuck SG. Fluorouracil and high-dose leucovorin in previously untreated patients with advanced adenocarcinoma of the pancreas: results of a phase II trial. J Clin Oncol 1991; 9:2128–2133.PubMedGoogle Scholar
  33. 32.
    Crown J, Casper ES, Botet J, Murray P, and Kelsen DP. Lack of efficacy of high-dose leucovorin and fluorouracil in patients with advanced pancreatic adenocarcinoma. J Clin Oncol 1991; 9:1682–1686.PubMedGoogle Scholar
  34. 33.
    Scheithauer W, Pfeffel F, Komek G, Marczell A, Wiltschke C, and Funovics J. A phase II trial of 5-fluorouracil, leucovorin, and recombinant alpha-2b-interferon in advanced adenocarcinoma of the pancreas. Cancer 1992; 70:1864–1866.PubMedCrossRefGoogle Scholar
  35. 34.
    Thieve NO, Pousette A, and Carlstrom K. Adenocarcinoma of the pancreas: a hormone sensitive tumour? A preliminary report on Nolvadex treatment. Clin Oncol 1983; 9:193–197.Google Scholar
  36. 35.
    Smith FP, Hoth DF, Levin B, Karlin DA, Macdonald JS, Woolley PV, and Schien PS. 5-fluorouracil, adriamycin and mitomycin-C(FAM) chemotherapy for advanced adenocarcinoma of the pancreas. Cancer 1980; 46:2014–2018.PubMedCrossRefGoogle Scholar
  37. 36.
    Bukowski RM, Schacter LP, Groppe CW, Hewlett JS, Weick JK, and Livingston RB. Phase II trial of 5-fluorouracil, adriamycin, mitomycin-C, and streptozotocin (FAM-S) in pancreatic carcinoma. Cancer 1982; 50:197–200.PubMedCrossRefGoogle Scholar
  38. 37.
    Gastrointestinal Tumor Study Group. Phase II studies of drug combinations in advanced pancreatic carcinoma: fluorouracil plus doxorubicin plus mitomycin C and two regimens of streptozotocin plus mitomycin C plus fluorouracil. J Clin Oncol 1986; 4:1794–1798.Google Scholar
  39. 38.
    Oster MW, Gray R, Panasci L, and Perry MC. Chemotherapy for advanced pancreatic cancer: a comparison of 5-fluorouracil, adriamycin, and mitomycin (FAM) with 5-fluorouracil, streptozotocin, and mitomycin (FSM). Cancer 1986; 57:29–23.PubMedCrossRefGoogle Scholar
  40. 39.
    Bukowski RM, Balcerzak SP, O’Bryan RM, Bonnet JD, and Chen TT. Randomized trial of 5-fluorouracil and mitomycin C with or without streptozotocin for advanced pancreatic cancer. Cancer 1983; 52:1577–1582.PubMedCrossRefGoogle Scholar
  41. 40.
    Dougherty J, Kelsen D, Kemeny N, et al. Advanced pancreatic cancer: a phase I–II trial of cisplatin, high dose cytarabine, and caffeine. J Natl Cancer Inst 1989; 81:1735–1738.PubMedCrossRefGoogle Scholar
  42. 41.
    Kelsen D, Hudis C, Niedzwiecki D, Dougherty J, Casper E, Botet J, Vinciguerra V, and Rosenbluth R. A phase III comparison trial of streptozotocin, mitomycin, and 5-fluorouracil with cisplatin, cytosine arabinoside, and caffeine in patients with advanced pancreatic carcinoma. Cancer 1991; 68:965–969.PubMedCrossRefGoogle Scholar
  43. 42.
    Mallinson CN, Rake MO, and Cocking JD. Chemotherapy in pancreatic cancer. Br Med J 1980; 281:1589–1591.PubMedCrossRefGoogle Scholar
  44. 43.
    Cullinan S, Moertel CG, Wieand HS, Schutt AJ, Krook JE, Foley JF, et al. A phase II trial on the therapy of advanced pancreatic carcinoma: evaluations of the Mallinson regimen and combined 5-fluorouracil, doxorubicin, and cisplatin. Cancer 1990; 65:2207–2212.PubMedCrossRefGoogle Scholar
  45. 44.
    Frey C, Twomey P, Keehn R, Elliott D, and Higgins G. Randomized study of 5-FU and CCNU in pancreatic cancer. Cancer 1981; 47:27–31.PubMedCrossRefGoogle Scholar
  46. 45.
    Glimelius B, Hoffman K, Graf W, et al. Cost-effectiveness of palliative chemotherapy in advanced gastrointestinal cancer. Ann Oncol 1995; 6:267–274.PubMedGoogle Scholar
  47. 46.
    Glimelius B, Hoffman K, Sjödén PO, Jacobson G, Seilström H, Enander LK, Linné T, and Svensson C. Chemotherapy improves survival and quality of life in advanced pancreatic and biliary cancer. Ann Oncol 1996; 7:593–600.PubMedCrossRefGoogle Scholar
  48. 47.
    Palmer KR, Kerr M, Knowles G, Cull A, Carter DC, and Leonard RC. Chemotherapy prolongs survival in inoperable pancreatic carcinoma. Br J Surg 1994; 81:882–885.PubMedCrossRefGoogle Scholar
  49. 48.
    Gastrointestinal Tumor Study Group. Pancreatic cancer: Adjuvant combined radiation and chemotherapy following curative resection. Arch Surg 1985; 120:899–903.CrossRefGoogle Scholar
  50. 49.
    Gastrointestinal Study Group. Further evidence of effective adjuvant combined radiation and chemotherapy following curative resection of pancreatic cancer. Cancer 1987; 59:2006–2010.CrossRefGoogle Scholar
  51. 50.
    Hoffman JP, Weese JL, Solin LJ, Engstrom P, Agarwal P, Barber LW, et al. A pilot study of preoperative chemoradiation for patients with localized adenocarcinoma of the pancreas. Am J Surg 1995; 169:71–77.PubMedCrossRefGoogle Scholar
  52. 51.
    Evans EB, Rich TA, Byrd DR, Cleary KR, Connelly JH, Levin B, et al. Preoperative chemoradiation and pancreaticoduodenectomy for adenocarcinoma of the pancreas. Arch Surg 1992; 127:1335–1339.PubMedCrossRefGoogle Scholar
  53. 52.
    Moertel CC, Fryta KS, Hahn RG, O’Connell MJ, Reitemeier RJ, Rubin J, et al. Therapy of locally unresectable pancreatic carcinoma: a randomized comparison of high dose (6,000 rads) radiation alone, moderate dose radiation (4,000 rads + 5 fluorouracil), antidose radiation + 5 fluorouracil: the Gastrointestinal Tumor Study Group. Cancer 1981; 48:1705–1710.PubMedCrossRefGoogle Scholar
  54. 53.
    Ashbury RF, Cnaan A, Johnson L, Harris J, Zaentz SD, and Haller DG. An Eastern Cooperative Oncology Group phase II study of single agent DHAD, VP-16, Aclacinomycin, or spirogermanium in metastatic pancreatic cancer. Am J Clin Oncol 1994; 17:166–169.CrossRefGoogle Scholar
  55. 54.
    Linke K, Pazdur R, Abbruzzese JL, Agani JA, Winn R, Bradof JE, Daugherty K, and Levin B. Phase II study of amonafide in advanced pancreatic adenocarcinoma. Invest New Drugs 1991; 9:353–356.PubMedCrossRefGoogle Scholar
  56. 55.
    Leichman CG, Tangen C, Macdonald JS, Leimert T, and Fleming TR. Phase II trial of amonafide in advanced pancreas cancer: a Southwest Oncology Group study. Invest New Drugs 1993; 11:219–221.PubMedCrossRefGoogle Scholar
  57. 56.
    Moertel CG, Schutt AJ, Reitemeier RJ, and Hahn RG. Therapy for gastrointestinal cancer with the nitrosoureas alone and in drug combination. Cancer Treatment Rep 1976; 60:729–732.Google Scholar
  58. 57.
    Gastrointestinal Tumor Study Group. Phase II trials of hexamethylmelamine, dianhydrogalactitol, razoxane, and β-2′-deoxythioguanosine as single agents against advanced measurable tumors of the pancreas. Cancer Treatment Rep 1985; 69:713–716.Google Scholar
  59. 58.
    Moore M, Maroun J, Robert F, Natale R, Neidhart J, Dallaire B, Sisk R, and Gyves J. Multicenter phase II study of brequinar sodium in patients with advanced gastrointestinal cancer. Invest New Drugs 1993; 11:61–65.PubMedCrossRefGoogle Scholar
  60. 59.
    Carter SK and Comis RL. The integration of chemotherapy into a combined modality approach for cancer treatment. Cancer Treatment Rev 1975; 2:193–214.CrossRefGoogle Scholar
  61. 60.
    Gastrointestinal Tumor Study Group. Phase II trials of maytansine, low-dose chlorozotocin, and high-dose chlorozotocin as single agents against advanced measurable adenocarcinoma of the pancreas. Cancer Treatment Rep 1985; 69:417–420.Google Scholar
  62. 61.
    Tilchen EJ, Fleming T, Mills G, Oishi N, Bonnett JD, Natale RB, Harker G, and Coltman CA. Phase II evaluation of diaziquone in pancreatic carcinoma: a Southwest Oncology Group study. Cancer Treatment Rep 1987; 71:1309–1310.Google Scholar
  63. 62.
    Bedikian AY, Karlin D, Stroehlein J, Valdivieso M, Korinek J, and Bodey GP. Phase II evaluation of dihydroxyanthracenedione (DHAD, NSC 301739) in patients with upper gastrointestinal tumors. Am J Clin Oncol 1983; 6:473–476.PubMedCrossRefGoogle Scholar
  64. 63.
    Moore DF, Pazdur R, Abbruzzese JL, Ajani JA, Dubovsky DW, Wade JL, et al. Phase II trial of edatrexate in patients with advanced pancreatic adenocarcinoma. Ann Oncol 1994; 5:286–287.PubMedGoogle Scholar
  65. 64.
    Casper E, Schwartz GK, Johnson B, and Kelsen DP. Phase II trial of edatrexate in patients with pancreatic adenocarcinoma. Invest New Drugs 1992; 10:313–316.PubMedCrossRefGoogle Scholar
  66. 65.
    Vaughn CB, Salmon SE, and Fleming TR. Phase II evaluation of esorubicin (4′deoxydoxorubicin) in pancreatic adenocarcinoma: a Southwest Oncology Group study. Invest New Drugs 1990; 8:81–85.PubMedCrossRefGoogle Scholar
  67. 66.
    Blayney DW, Goldberg DA, Leong LA, Carr BI, and Doroshow JH. Phase II trial of epirubicin in advanced pancreatic adenocarcinoma. Cancer Treatment Rep 1986; 70:683–684.Google Scholar
  68. 67.
    Sternberg CN, Magill GB, Cheng EW, Applewhite A, and Sordillo PP. Etoposide (VP-16) in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol 1988; 11:172–173.PubMedCrossRefGoogle Scholar
  69. 68.
    Casper ES, Schwartz GK, and Kelsen DP. Phase II trial of fazarabine (arabinofuranosyl-5-azacytidine) in patients with advanced pancreatic adenocarcinoma. Invest New Drugs 1992; 10:205–209.PubMedCrossRefGoogle Scholar
  70. 69.
    Kilton LJ, Benson AB, Greenberg A, Johnson P, Shapiro C, Blough R, French S, and Weidner L. Phase II trial of fludarabine phosphate for adenocarcinoma of the pancreas. An Illinois Cancer Center study. Invest New Drugs 1992; 10:201–204.Google Scholar
  71. 70.
    Mittelman A, Magill GB, Raymond V, Sternberg CN, Cheng EW, Sordillo PB, and Young CW. Phase II trial of idarubicin in patients with pancreatic cancer. Cancer Treatment Rep 1987; 71:657–658.Google Scholar
  72. 71.
    Hubbard KP, Pazdur R, Ajani JA, Braud E, Blaustein A, King M, Llenado-Lee M, Winn R, Levin B, and Abbruzzese JL. Phase II evaluation of iproplatin in patients with advanced gastric and pancreatic cancer. Am J Clin Oncol 1992; 15:524–527.PubMedGoogle Scholar
  73. 72.
    Lessner HE, Valenstein S, Kaplan R, DeSimone P, and Yunis A. Phase II study of L-asparaginase in the treatment of pancreatic cancer. Cancer Treatment Rep 1980; 64: 1359–1361.Google Scholar
  74. 73.
    Sternberg CN, Magill GB, Sordillo PP, Cheng E, and Currie VE. Phase II evaluation of m-AMSA (4′-(9-acridinylamino)-methane-sulfon-m-anisidide) in patients with adenocarcinoma of the pancreas. Am J Clin Oncol 1983; 6:459–462.PubMedCrossRefGoogle Scholar
  75. 74.
    Horton J, Gelber RD, Engstrom P, Falkson G, Moertel C, Brodovsky H, and Douglass H. Trials of a single-agent and combination chemotherapy for advanced cancer of the pancreas. Cancer Treatment Rep 1981; 65:65–68.Google Scholar
  76. 75.
    Smith DB, Kenny JB, Scarffe JH, and Maley WV. Phase II evaluation of melphalan in adenocarcinoma of the pancreas. Cancer Treat Rep 1985; 69:917–918.PubMedGoogle Scholar
  77. 76.
    Brown TD, Goodman PJ, Fleming TR, Baker LH, and Macdonald JS. Phase II trial of menogaril in adenocarcinoma of the pancreas. A Southwest Oncology Group study. Invest New Drugs 1991; 9:77–78.Google Scholar
  78. 77.
    Sternberg CN, Magill GB, Cheng EW, and Hollander P. Phase II trial of menogarol in the treatment of advanced adenocarcinoma of the pancreas. Am J Clin Oncol 1988; 11:174–176.PubMedCrossRefGoogle Scholar
  79. 78.
    Kraut EH, Fleming T, Macdonald JS, Spiridonidis CH, Bradof JE, and Baker LH. Phase II trial of merbarone in pancreatic cancer: a Southwest Oncology Group study. Am J Clin Oncol 1993; 16:327–328.PubMedCrossRefGoogle Scholar
  80. 79.
    Jones DV, Ajani JA, Winn RJ, Daugherty KR, Levin B, and Krakoff IH. A phase II study of merbarone in patients with adenocarcinoma of the pancreas. Cancer Invest 1993; 11:667–669.PubMedCrossRefGoogle Scholar
  81. 80.
    Moertel CG, Douglass HO, Hanley J, and Carbone PP. Phase II study of methyl-CCNU in the treatment of advanced pancreatic carcinoma. Cancer Treatment Rep 1976; 60:1659–1661.Google Scholar
  82. 81.
    Sternberg CN, Magill GB, Sordillo PP, Cheng EW, and Kemeny N. Phase II evaluation of metoprine in advanced pancreatic adenocarcinoma. Cancer Treatment Rep 1984; 68:1053–1054.Google Scholar
  83. 82.
    Inamasu MS, Oishi N, Chen TT, Kraut EH, Grozea PN, Costanzi JJ, and Bonnet JD. Phase II study of mitoguazone in pancreatic cancer: a Southwest Oncology Group study. Cancer Treatment Rep 1986; 70:531–532.Google Scholar
  84. 83.
    DeSimone PA, Gams R, and Bartolucci A. Weekly mitoxantrone in the treatment of pancreatic carcinoma. A Southeastern Cancer Study Group Trial. Cancer Treatment Rep 1986; 70:929–930.Google Scholar
  85. 84.
    Abbruzzese JL, Gholson CF, Daugherty K, Larson E, DuBrow R, Berlin R, and Levin B. A pilot clinical trial of cholecystokinin receptor antagonist MK-329 in patients with advanced pancreatic cancer. Pancreas 1992; 17:165–171.CrossRefGoogle Scholar
  86. 85.
    Weiner LM, Harvey E, Padavic-Shaller K, Willson JKV, Walsh C, LaCreta F, et al. Phase II multicenter evaluation of prolonged murine monoclonal antibody 17-1A therapy in pancreatic cancer. J Immunother 1993; 13:110–116.CrossRefGoogle Scholar
  87. 86.
    Whitehead RP, Jacobson J, Brown TD, Taylor SA, Weiss GR, and Macdonald JS. Phase II trial of paclitaxel and granulocyte colony-stimulating factor in patients with pancreatic carcinoma: a Southwest Oncology Group study. J Clin Oncol 1997; 15:2414–2419.PubMedGoogle Scholar
  88. 87.
    Kraut EH, Fleming T, Segal M, Neidhart JA, Behrens BC, and MacDonald J. Phase II study of pibenzimol in pancreatic cancer. Invest New Drugs 1991; 9:95–96.PubMedCrossRefGoogle Scholar
  89. 88.
    Patel SR, Kvols LK, Rubin J, O’Connell MJ, Edmonson JH, Ames MM, and Kovach JS. Phase I‐II study of pibenzimol hydrochloride (NSC 322921) in advanced pancreatic carcinoma. Invest New Drugs 1991; 9:53–57.PubMedCrossRefGoogle Scholar
  90. 89.
    Jenkins TR, Tangen C, Macdonald JS, Weiss G, Chapman R, and Hantel A. A phase II trial of piroxantrone in adenocarcinoma of the pancreas. A Southwest Oncology Group study. Invest New Drugs 1993; 11:329–331.PubMedCrossRefGoogle Scholar
  91. 90.
    Canobbio L, Boccardo F, Cannata D, Gallotti P, and Epis R. Treatment of advanced pancreatic carcinoma with somatostatin analogue BIM 23014. Cancer 1992; 69:648–650.PubMedCrossRefGoogle Scholar
  92. 91.
    Scheithauer W, Kornek G, Haider K, and Depisch D. Unresponsiveness of pancreatic adenocarcinoma to antioestrogen therapy. Eur J Cancer 1990; 26:851–852.PubMedCrossRefGoogle Scholar
  93. 92.
    Ajani JA, Pazdur R, Winn RJ, Abbruzzese JL, Levin B, Belt R, Young J, Patt YZ, and Krakoff IH. Phase II study of intravenous 6-thioguanine in patients with advanced carcinoma of the pancreas. Invest New Drugs 1991; 9:369–371.PubMedGoogle Scholar
  94. 93.
    Brown TD, Goodman P, Fleming T, Macdonald JS, Hersh EM, and Braun TJ. A phase II trial of recombinant tumor necrosis factor in patients with adenocarcinoma of the pancreas: a Southwest Oncology Group study. J Immunother 1991; 10:376–378.PubMedCrossRefGoogle Scholar
  95. 94.
    Pazdur R, Ajani JJ, Abbruzzese JL, Belt RJ, Dakhil SR, Dubovsky D, et al. Phase II evaluation of fluorouracil and recombinant α-2a-interferon in previously untreated patients with pancreatic adenocarcinoma. Cancer 1992; 70:2073–2076.PubMedCrossRefGoogle Scholar
  96. 95.
    Rosvold E, Schilder R, Walczak J, DiFino SM, Flynn PJ, Banerjee TK, et al. Phase II trial of PALA in combination with 5-fluorouracil in advanced pancreatic cancer. Cancer Chemother Pharmacol 1992; 29:305–308.PubMedCrossRefGoogle Scholar
  97. 96.
    Morrell LM, Bach A, Richman SP, Goodman P, Fleming TR, and Macdonald JS. A phase II multi-institutional trial of low-dose N-(phosphonacetyl)-L-aspartate and high-dose 5-fluorouracil as a short-term infusion in the treatment of adenocarcinoma of the pancreas. Cancer 1991; 67:363–366.PubMedCrossRefGoogle Scholar
  98. 97.
    Ardalan B, Singh G, and Silberman H. A randomized phase I and II study of short-term infusion of high-dose fluorouracil with or without N-(phosphonacetyl)-L-aspartic acid in patients with advanced pancreatic and colorectal cancer. J Clin Oncol 1988; 6:1053–1058.PubMedGoogle Scholar
  99. 98.
    Wils J, Bleiberg H, Buyse M, Wagener DT, Splinter T, Veenhoe C, Herben M, and Duez N. An EORTC Gastrointestinal Group Phase II evaluation of epirubicin combined with ifosfamide in advanced adenocarcinoma of the pancreas. Eur J Cancer Clin Oncol 1989; 25:1119–1120.PubMedCrossRefGoogle Scholar

Copyright information

© Springer Science+Business Media New York 1998

Authors and Affiliations

  • Margaret Tempero

There are no affiliations available

Personalised recommendations